Intramyocardial injection of bone marrow mononuclear cells exhibited better cell survival at 6 weeks (P<0.01) and preserved fractional shortening (P<0.05) compared to other cell types and PBS.
Does intramyocardial injection of different adult stem cell types improve cell survival and cardiac function in a murine model of myocardial infarction?
In a murine model of myocardial infarction, bone marrow mononuclear cells exhibited better survival and more robust preservation of cardiac function compared to mesenchymal stem cells, skeletal myoblasts, and fibroblasts.
p-value: p=<0.05
BACKGROUND: A comparative analysis of the efficacy of different cell candidates for the treatment of heart disease remains to be described. This study is designed to evaluate the therapeutic efficacy of 4 cell types in a murine model of myocardial infarction. METHODS AND RESULTS: Bone marrow mononuclear cells (MN), mesenchymal stem cells (MSC), skeletal myoblasts (SkMb), and fibroblasts (Fibro) expressing firefly luciferase (Fluc) and green fluorescence protein (GFP) were characterized by flow cytometry, bioluminescence imaging (BLI), and luminometry. Female FVB mice (n=70) underwent LAD ligation and intramyocardially received one cell type (5x10(5)) or PBS. Cell survival was measured by BLI and by TaqMan PCR. Cardiac function was assessed by echocardiography and invasive hemodynamic measurements. Fluc expression correlated with cell number in all groups (r(2)>0.93). In vivo BLI revealed acute donor cell death of MSC, SkMb, and Fibro within 3 weeks after transplantation. By contrast, cardiac signals were still present after 6 weeks in the MN group, as confirmed by TaqMan PCR (P<0.01). Echocardiography showed significant preservation of fractional shortening in the MN group compared to controls (P<0.05). Measurements of left ventricular end-systolic/diastolic volumes revealed that the least amount of ventricular dilatation occurred in the MN group (P<0.05). Histology confirmed the presence of MN, although there was no evidence of transdifferentiation by donor MN into cardiomyocytes. CONCLUSIONS: This is the first study to show that compared to MSC, SkMB, and Fibro, MN exhibit a more favorable survival pattern, which translates into a more robust preservation of cardiac function.
Bogt et al. (Tue,) conducted a other in myocardial infarction (n=70). Bone marrow mononuclear cells (MN) vs. MSC, SkMb, Fibro, or PBS was evaluated on Cell survival and cardiac function (p=<0.05). Intramyocardial injection of bone marrow mononuclear cells exhibited better cell survival at 6 weeks (P<0.01) and preserved fractional shortening (P<0.05) compared to other cell types and PBS.